Pediatric nursing

Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

Retrieved on: 
Tuesday, November 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Linda, Development of the nervous system, American Epilepsy Society, Dravet syndrome, Risk, Cognition, Therapy, International League Against Epilepsy, Ann, Government budget balance, OLE, Stoke, Neurology, Cerebrospinal fluid, Associate, SUDEP, Patient, Intellectual disability, Hospital, Autonomic nervous system, Caregiver, Movement, Medicine, European Journal of Paediatric Neurology, Prognosis, ASO, Seizure, Plasma, FDA, Diagnosis, EMA, Disease, Safety, Sleep, Adolescence, Lurie Children's Hospital, 2021 Essex County Council election, DMPK, AES, MB, Language, Annual general meeting, Senior, SCN1A, Death, Quality of life, Feinberg School of Medicine, Pharmaceutical industry, Paint, Vaccine, Epilepsy, Pharmacokinetics, Pediatric nursing, BioAnalyt

The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.

Key Points: 
  • The company is advancing STK-001 as potentially the first medicine to treat the underlying cause of Dravet syndrome.
  • Compared with the general epilepsy population, people living with Dravet syndrome have a higher risk of sudden unexpected death in epilepsy, or SUDEP.
  • STK-001 is an investigational new medicine for the treatment of Dravet syndrome currently being evaluated in ongoing clinical trials.
  • Stokes first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

A Call to Action for Canada’s Kids from Children’s Healthcare Canada, the Canadian Paediatric Society and the Canadian Association of Paediatric Nurses

Retrieved on: 
Friday, November 18, 2022
Transfer, COVID-19, CPS, Health, Risk, Hospital, Learning, Patient, Nursing, Canadian Paediatric Society, Child, Rehabilitation, Premier, Pediatric nursing, Investment, National Child Abuse Prevention Month, Medicine, Increase

The current crisis in child and youth healthcare represents both a challenge and an opportunity for learning.

Key Points: 
  • The current crisis in child and youth healthcare represents both a challenge and an opportunity for learning.
  • Childrens Healthcare Canada, the Canadian Paediatric Society (CPS) and the Canadian Association of Paediatric Nurses (CAPN) are calling on governments to move beyond jurisdictional constraints, identify shared priorities and work collaboratively towards addressing the health system crisis impacting Canadas eight million children and youth.
  • Leverage global partnerships to learn how international jurisdictions are managing pediatric healthcare capacity challenges and developing responses to emerging healthcare priorities.
  • Together, Childrens Healthcare Canada, the Canadian Paediatric Society and the Canadian Association of Pediatric Nurses urge federal, territorial and provincial leaders in Canada to work together to resolve the current crisis in childrens healthcare, develop a new vision and commit resources to measurably improve the health of Canadas children and youth.

greymatter.io Simplifies Modern Application Networking Platform

Retrieved on: 
Wednesday, October 26, 2022
Telecommunications, Venture Capital, Software, Networks, Internet, Professional Services, Technology, Security, API, JSON, SOAR, MTL, YAML, Intelligence, SIEM, ROI, Automation, Pediatric nursing, Helm, Spire, Compliance, Telemetry, EDR, Founder, CEO, Service mesh, DevOps, Government, Environment, Solution, Language, Video game console, Risk management, Prometheus

greymatter.io, the leading provider of an all-in-one, enterprise application networking platform widely-deployed worldwide throughout mission-critical defense and intelligence environments, announced the general availability of its latest platform release today.

Key Points: 
  • greymatter.io, the leading provider of an all-in-one, enterprise application networking platform widely-deployed worldwide throughout mission-critical defense and intelligence environments, announced the general availability of its latest platform release today.
  • Built from the ground up to simplify the complexity of modern application networking, the new release is focused on improving ease of use for enterprise DevOps and platform engineering teams by implementing low-code configuration, automating CI/CD workflows, and further enabling zero-trust security across hybrid, multi-cloud and on-premise environments.
  • Simplified Configuration: Reduce platform configuration time with 90% less configuration code than JSON, YAML or Helm charts using greymatter.ios new CUE-based configuration language and Dev Kit to streamline application networking setup, deployment, and delivery with full support for GitOps.
  • Named a Leader and Outperformer in the 2022 GigaOm Radar Report for Service Mesh, our enterprise application networking platform delivers unprecedented control, security, and visibility across any hybrid or multi-cloud environment.

Up to 410,000 Accounts have engaged in AMAX#1 mining, Armonia lifted an "Everything Farmable" trending wave

Retrieved on: 
Friday, September 23, 2022
EOS, Child, Pediatric nursing, BTC, Industry, Mining, Technology, APL, Ecosystem, Miner, Research, AMAX, Blockchain, Cryptocurrency, SS Armonia (1924)

As the height of the mainstream blockchain like BTC and EOS continues to rise, the mining arithmetic power is becoming more and more concentrated.

Key Points: 
  • As the height of the mainstream blockchain like BTC and EOS continues to rise, the mining arithmetic power is becoming more and more concentrated.
  • All participants can share the dividends of the development of the Armonia ecosystem, thus creating a virtuous cycle of Armonia's ecosystem building.
  • Armonia AMAX#1 mining pool, since its official launch on August 28, has quickly lifted a mining rush among users and set off a boom in the blockchain mining industry.
  • According to the ecosystem construction plan, Armonia ecosystem mining pool will be opened from time to time, which is expected to open once every quarter.

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Retrieved on: 
Monday, September 19, 2022
Adult, Bardet–Biedl syndrome, Endocrine Society, Leptin receptor, Microdeletion syndrome, Department, MC4R, FDA, UCL Great Ormond Street Institute of Child Health, MD, Pediatrics, Adolescence, Poster, European Society for Medical Oncology, Obesity, Patient, Mental health, BBS, POMC, Very early onset inflammatory bowel disease, Nasdaq, Ageing, Caregiver, EC, Polyphagia, ESPE, LEPR, GLOBE, Pediatric endocrinology, Disease, Pharmaceutical industry, Residential care, Setmelanotide, Pediatric nursing, Proopiomelanocortin, Rhythm

BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, announced the presentation of new findings on the burden of hyperphagia and obesity on patients with Bardet-Biedl syndrome (BBS) and their caregivers during the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2022) held in Rome on Sept. 15 to 17.

Key Points: 
  • Rhythm and its collaborators delivered one poster and three oral presentations during ESPE 2022, including data from new analyses that showed setmelanotide achieved substantial weight loss benefit in adolescent and pediatric patients with rare MC4R pathway diseases across three separate pivotal trials.
  • CARE-BBS participants at the time of the survey were residents of the United States (n=60), Canada (n=62), United Kingdom (n=59) or Germany (n=61).
  • In addition, the findings illustrate how the negative impact of hyperphagia on caregivers affects family dynamics, emotional well-being, and caregiver employment.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

FLORIDA SOUTHERN COLLEGE DOCTOR OF NURSING PRACTICE STUDENTS PRESENT CAPSTONE PROJECTS

Retrieved on: 
Thursday, August 11, 2022
Blood, FSC, Assistant, College, U.S. News & World Report, RN, Education, The Princeton Review, ANP, Student, Program, Health, Multimedia, MSN, Pediatric nursing, Florida Southern College, Assistant professor, Learning, Transitional care, AACSB, Graduate, COL, News, APRN, 2005 NCAA Division I-A football season, RHIT, User experience, Travel, Literature, MS, NP-C, School, CPNP, DNP, CRNA, Curriculum, Population, Interprofessional education, Business, U.S. News & World Report Best Colleges Ranking, Advance care planning, Type 2 diabetes, View, Associate, Outline of health sciences, Sarcopenia, Medicine, Fortune, Nursing

LAKELAND, Fla., Aug. 11, 2022 /PRNewswire/ -- Members of the second graduating class of the Florida Southern College Doctor of Nursing Practice program presented their capstone project posters in the Joe K. and Alberta Blanton Nursing Building, on August 4th, 2022.

Key Points: 
  • LAKELAND, Fla., Aug. 11, 2022 /PRNewswire/ -- Members of the second graduating class of the Florida Southern College Doctor of Nursing Practice program presented their capstone project posters in the Joe K. and Alberta Blanton Nursing Building, on August 4th, 2022.
  • The seven-member cohort completed community- and practice- based health care improvement projects.
  • "I am delighted with the results of the DNP projects completed by students in the summer 2022 graduating DNP cohort," Dr. Michael said.
  • Florida Southern has a 14:1 student-to-faculty ratio, is an award-winning national leader in engaged learning, and boasts 30 NCAA Division II National Championships.

Carbon Biosciences Launches with $38 Million Series A Financing to Advance Novel Gene Therapy Platform and Pipeline

Retrieved on: 
Tuesday, June 21, 2022
Research, Finance, Genetics, Clinical Trials, Professional Services, Biotechnology, Health, Other Science, Science, Yan, Beverly Davidson, Partner, MBBS, University, Director, LinkedIn, Pressure, CFTR, Vertex, Inflammation, National Institute of Dental and Craniofacial Research, Therapy, Company, University College London, Tissue, AAV, Technology, CEO, University of Iowa, MRCP, Founder, Lung, Alnylam Pharmaceuticals, Board, University of Kansas, Parvoviridae, Industry, Tropism, UCL Great Ormond Street Institute of Child Health, Chairperson, FRCP, List of life sciences, Lists of diseases, Patient, Multimedia, Cystic fibrosis, Senior, CBO, Cystic Fibrosis Foundation, Gene, Research, Program, Infection, Doctor of Philosophy, UCL, Center, Roy J. and Lucille A. Carver College of Medicine, Pharmaceutical industry, Management, Pediatric nursing, Photis Kontoglou, Molecular medicine, Engelhardt, Microbiology

Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.

Key Points: 
  • Carbon Biosciences (Carbon), a Longwood Fund founded biotech company and emerging leader in the development of novel parvovirus-derived gene therapies, today announced a $38 million Series A financing led by Agent Capital.
  • Carbon is harnessing novel parvovirus vectors that can deliver larger gene therapy payloads with enhanced tissue specificity and with minimal neutralizing immunity.
  • Carbons technology will enable a diversified pipeline with potential applications across the wide range of tissues impacted in many unaddressed diseases.
  • Carbons scientific co-founders and scientific advisory board members are among the most experienced thought leaders in the gene therapy field.

The Galien Foundation Announces Winners of the 2022 Prix Galien UK Awards at the Natural History Museum, London

Retrieved on: 
Friday, May 13, 2022
Social media, Bill, Foundation, University of Liverpool, Health, Paganini Competition, Veterinary medicine, Therapy, Imperial College London, Edinburgh, Nobel Prize, Tropical medicine, Respiratory Medicine, Hygiene, Queen Mary University of London, Internal medicine, London School of Hygiene & Tropical Medicine, University, College, University of Edinburgh College of Medicine and Veterinary Medicine, Former, University of Edinburgh, Committee, Education, Management, Dentistry, Pharmaceutical industry, Medicine, Pediatric nursing, Biostatistics

LONDON, May 13, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, announced winners for the 2022 Prix Galien UK Awards last night at the Natural History Museum, London. Awards for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" were awarded to industry leaders dedicated to innovation that improves the human condition. In conjunction with the Prix Galien UK Awards, The Galien Foundation also announced winners for the 2022 Prix Galien International Awards for "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product" and "Best Vaccine."

Key Points: 
  • Former Chief Executive Officer of the Bill & Melinda Gates Foundation, Seattle, WA
    Professor of Internal Medicine and Therapeutics & Founder, Former President
    Honorary Distinguished Professor of Medicine, Imperial College, Committee Chair, Prix Galien UK Awards Committee
    The Galien Foundation fosters, recognises and rewards excellence in scientific innovation to improve the state of human health.
  • The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.
  • Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.

On First Anniversary of Pediatric Mental Health State of Emergency Children's Hospital Colorado Reports Increase of Almost 50% in Emergency Behavioral Health Visits as Compared to 2021

Retrieved on: 
Thursday, May 5, 2022
Parent, Strengthening Kids' Interest in Learning and Libraries Act, Investment, United States Public Health Service, Children's Hospital, Q&A, Gaps, AURORA, NFL, Centers for Disease Control and Prevention, Time, CDC, Pediatric nursing, Adolescence, Patient, Partnership, Caregiver, Anxiety, Center, Grandparent, MD, EDS, Public policy, Health, ARPA, Mental health, Population health, Solution, Children's Hospital Colorado Foundation, Mental, Social media, Toy, Medicine, Child

AURORA, Colo., May 5, 2022 /PRNewswire/ -- Since Children's Hospital Colorado declared a youth mental health state of emergency one year ago, the pediatric health system has continued to see record numbers of kids and youth in mental health crises. Based on recent data, there has been a 47% increase in patients visiting the hospital's emergency departments (EDs) for behavioral health concerns when compared to first quarter 2021 and a 136% increase above first quarter 2019, before the pandemic began.

Key Points: 
  • Parents, families and the community can all play a role in urging lawmakers to take action to improve system accountability, coordination and access to mental health services.
  • This year Colorado state lawmakers are also poised to formalize the new Behavioral Health Administration to better align all state-funded mental health and substance use programs.
  • "Children's Colorado applauds Colorado lawmakers and Governor Polis for taking aggressive steps to invest in youth mental health.
  • Reach out now to your representative and senators to urge passage of the Strengthen Kids' Mental Health Now Act (H.R.

The Galien Foundation Debuts 2022 Prix Galien UK Award Candidates in "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" Categories

Retrieved on: 
Monday, May 2, 2022
Hygiene, Education, Foundation, London School of Hygiene & Tropical Medicine, Queen Mary University of London, College, Liverpool School of Tropical Medicine, Edinburgh, Therapy, University of Liverpool, University of Edinburgh College of Medicine and Veterinary Medicine, University of Edinburgh, Veterinary medicine, Respiratory Medicine, Social media, Paganini Competition, University, Health, Nobel Prize, Dentistry, Pharmaceutical industry, Medicine, Biostatistics, Pediatric nursing

LONDON, May 2, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, today announced the 2022 Prix Galien UK Award candidates for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution." Winners will be announced during the Prix Galien UK Awards Ceremony on 12 May at the Natural History Museum in London.

Key Points: 
  • Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives.
  • The Foundation oversees and directs activities in the UK for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries and Africa.
  • The Prix Galien was created in 1970 by Roland Mehl in honour of Galien, the father of medical science and modern pharmacology.
  • Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research.